Zhejiang Jingxin Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the board of directors guarantee that the content of this announcement is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
The Company held the third meeting of the ninth board of directors on January 12, 2026, to review and approve the proposal on the appointment of auditors for the issuance and listing of H shares, agreeing to appoint Hong Kong Lee & Associates CPA Limited (hereinafter referred to as "Hong Kong Lee") as the auditor for the issuance of overseas listed shares (H shares) and the application for listing on the main board of The Stock Exchange of Hong Kong Limited (hereinafter referred to as "Hong Kong Stock Exchange"). This proposal is subject to approval by the shareholders' meeting. The specific circumstances are announced as follows: